Vanda Pharmaceuticals (VNDA) Misses Q4 EPS by 83c, provides guidance
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.13 +0.39%
Revenue Growth %: +24.1%
Financial Fact:
Research and development: 7.29M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +24.1%
Financial Fact:
Research and development: 7.29M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of ($1.81), $0.83 worse than the analyst estimate of ($0.98). Revenue for the quarter came in at $33.22 million versus the consensus estimate of $59.28 million.
GUIDANCE:
Vanda Pharmaceuticals sees FY2026 revenue of $230-260 million, versus the consensus of $271.3 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. and Denmark close in on a Greenland deal - Reuters
- SmartKem (SMTK) files for 15.13M share offering by selling stockholders
- Leidos wins $85m Air Force contract for aerospace design
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
